NEWS DETAIL

Human medicines European public assessment report (EPAR): Koselugo, selumetinib, Date of authorisation: 17/06/2021, Revision: 9, Status: Authorised

Koselugo is a medicine used to treat plexiform neurofibromas, benign (non-cancerous) tumours along the nerves, when they cause symptoms and cannot be removed by surgery in adults a…

该文章暂未提取到完整正文,已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。

Productos relacionados con este articulo

Estos productos se asociaron automaticamente a partir del titulo, el resumen y el contenido del articulo.

Preguntas frecuentes

Which products are related to this article?

The system matched these relevant products from the article content: Selumetinib de SEMEDX Lucius Smectinib Koselugo – Comprar en línea Selumetinib de SEMEDX DABRADX Dabrafenib 75 mg.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.

WhatsApp WhatsApp WeChat WeChat